<?xml version="1.0" encoding="UTF-8"?>
<p>Between July 2011 and December 2012, 96 patients who achieved MR
 <sup>4.5</sup> were enrolled in the STAT2 trial. These patients started treatment in the consolidation phase and were defined as the safety analysis set. Seventy-eight patients entered the TFR phase and were analyzed as the full analysis set for TFR. The baseline demographics of the safety and full analysis sets are shown in 
 <xref rid="t1-1031835" ref-type="table">Table 1</xref>.
</p>
